[go: up one dir, main page]

MY198715A - Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative - Google Patents

Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative

Info

Publication number
MY198715A
MY198715A MYPI2020002658A MYPI2020002658A MY198715A MY 198715 A MY198715 A MY 198715A MY PI2020002658 A MYPI2020002658 A MY PI2020002658A MY PI2020002658 A MYPI2020002658 A MY PI2020002658A MY 198715 A MY198715 A MY 198715A
Authority
MY
Malaysia
Prior art keywords
pancreatic beta
benzyloxy
hex
phenyl
beta cells
Prior art date
Application number
MYPI2020002658A
Inventor
Dae Hoon Kim
Chun Hwa Kim
Sun Hee Lee
Goeun Yang
Seung Jun Kang
Hyo Sun Choi
Original Assignee
Hyundai Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyundai Pharm Co Ltd filed Critical Hyundai Pharm Co Ltd
Publication of MY198715A publication Critical patent/MY198715A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/02—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2
    • C07D317/06—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2 condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention provides a use of a 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative for protecting pancreatic beta cells. The 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative according to the present invention resolves a side effect in which conventionally developed agents for treating diabetes induce apoptosis of pancreatic beta cells through excitotoxic reactions, thereby causing a secondary failure in which an insulin secretory function is not controlled. The 3-(4- (benzyloxy)phenyl)hex-4-inoic acid derivative according to the present invention promotes insulin secretion only when glucose concentration is increased, thereby protecting the pancreatic beta cells from apoptosis and restoring the insulin secretory function of the pancreatic beta cells. Therefore, according to the present invention, the 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative exhibits an excellent pancreatic beta cell protection effect, when administered as a primary selective agent for diabetes and also when administered to a patient having pancreatic beta cells damaged by the use of other drugs, which are primary selection agents for diabetes and cause a secondary failure; and restores the insulin secretory function of pancreatic beta cells, thereby being useful for treating type II diabetes in a patient of which the blood glucose is not regulated in a normal manner by using an agent for promoting insulin secretion. [Fig. 12]
MYPI2020002658A 2017-12-01 2018-12-03 Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative MY198715A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762593350P 2017-12-01 2017-12-01
PCT/KR2018/015201 WO2019108046A1 (en) 2017-12-01 2018-12-03 Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative

Publications (1)

Publication Number Publication Date
MY198715A true MY198715A (en) 2023-09-19

Family

ID=66665761

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2020002658A MY198715A (en) 2017-12-01 2018-12-03 Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative

Country Status (5)

Country Link
KR (1) KR102090079B1 (en)
MY (1) MY198715A (en)
SG (1) SG11202004891PA (en)
WO (1) WO2019108046A1 (en)
ZA (1) ZA202003028B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7607596B2 (en) 2019-05-31 2024-12-27 ヒュンダイ ファーム カンパニー リミテッド Novel crystal form of 3-(4-(benzyloxy)phenyl)hex-4-ynoic acid derivative
KR102270026B1 (en) * 2020-01-31 2021-06-28 현대약품 주식회사 Quality evaluation method of (3S)-3-(4-(3-(1,4-dioxaspiro[4,5]dec-7-en-8-yl)benzyloxy)phenyl)hex-4-ynoic acid
KR102699076B1 (en) * 2021-04-01 2024-08-27 현대약품 주식회사 Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative
CN116509830A (en) * 2023-06-16 2023-08-01 桂林医学院 Application of methyl ferulic acid in preparation of insulin secretion promoting agent and synthetic agent
WO2025253265A1 (en) * 2024-06-03 2025-12-11 현대약품 주식회사 Pharmaceutical composition for preventing or treating diabetes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100354912B1 (en) * 2000-06-21 2002-10-05 박병현 Antidiabetic Amomum xanthoides extract and composition containing the extract as effective ingredient
KR20100104482A (en) * 2009-03-18 2010-09-29 한림대학교 산학협력단 Puple corn anthocyanins with excellent blood glucose control activity and efficient protective activity for diabetic loss of pancreatic beta cells
KR101121954B1 (en) * 2010-05-13 2012-03-09 아주대학교산학협력단 Composition for preventing or treating diabetes comprising 1,2,3-Benzentricarboxylic acid
EP2595952B1 (en) * 2010-07-23 2020-11-18 Connexios Life Sciences Pvt. Ltd. Agonists of gpr40
KR20140097837A (en) * 2013-01-30 2014-08-07 부산대학교 산학협력단 PADINA ARBORESCENS EXTRACT FOR PROMOTING INSULIN SECRETION AND PROTECTING PANCREATIC β CELL
KR101569522B1 (en) * 2013-04-18 2015-11-17 현대약품 주식회사 Novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, preparation method thereof, and pharmaceutical composition for use in preventing or treating metabolic diseases containing the same as an active ingredient
MX387086B (en) * 2014-10-17 2025-03-19 Hyundai Pharm Co Ltd COMPOUND PREPARATION, CONTAINING A NOVEL DERIVATIVE OF 3-(4-(BENZYLOXY)PHENYL)HEX-4-YNOIC ACID AND ANOTHER ACTIVE INGREDIENT, FOR THE PREVENTION OR TREATMENT OF METABOLIC DISEASES

Also Published As

Publication number Publication date
ZA202003028B (en) 2021-08-25
KR20190141007A (en) 2019-12-20
SG11202004891PA (en) 2020-06-29
WO2019108046A1 (en) 2019-06-06
KR102090079B1 (en) 2020-03-17

Similar Documents

Publication Publication Date Title
MY198715A (en) Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative
JOP20220024A1 (en) Gipr-agonist compounds
EA201270666A1 (en) COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR REDUCING URIC ACID LEVEL
NO20083026L (en) Therapeutic agent for diabetes
Gordon et al. Remittive effects of intramuscular alefacept in psoriasis.
BRPI0911035B8 (en) pyrrolidinone glycokinase activators
EP4596042A3 (en) Methods for treating diabetes, hepatitis, and/or inflammatory liver disease
WO2020109526A3 (en) Oxyntomodulin peptide analog formulations
AU2012366182A8 (en) Method of treating diabetes using non-glycosylated apolipoprotein A-IV
Griffiths et al. Contemporary management of cytomegalovirus infection in transplant recipients: guidelines from an IHMF workshop, 2007.
NO20090205L (en) Cyclic derivatives as modulators of chemokine receptor activity
EA201391063A1 (en) APOLIPOPROTEIN A-IV AS ANTIDIABETIC PEPTIDE
MX2022008681A (en) Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs.
WO2014193832A3 (en) Glucagon-like peptide 1 (glp-1) receptor modulators and uses thereof in regulating blood glucose levels
Creisson et al. Captopril/hydrochlorothiazide combination in elderly patients with mild-moderate hypertension. A double-blind, randomized, placebo-controlled study.
EP4324522A3 (en) Methods of treating fabry patients having renal impairment
AU2003288793A8 (en) Pharmaceutical compound containing silymarin and carbopol?, production method thereof and use of same as a regenerator of tissue and pancreatic cells with endogenous secretion damaged by diabetes mellitus
Herink et al. Serious complications following gluteal injection of silicone
Riet et al. Radiation therapy of sinonasal natural killer/T-cell lymphoma
WO2022271944A3 (en) Compositions and methods for treatment of gaucher disease
US9101611B1 (en) Use of sulfonylurea (Glimepiride) to lower blood glucose
Sarbu et al. Preliminary data on post-pancreatectomy diabetes mellitus treated by islet-cell autotransplantation
Spelsberg et al. Significance of immediate affixation of a hard contact lens in the emergency treatment of severe alkali burns of the cornea (case report)
Scheen Alogliptin (Vipidia): a selective DPP-4 inhibitor with a good cardiovascular safety
Fabiny Ask the doctor. I've had osteoporosis for several years, and I've been taking alendronate (Fosamax) once a week. I wasn't very good at remembering to take it regularly, so my doctor recently recommended that I start on once-a-year infusions of zoledronic acid (Reclast). Will it work as well to prevent me from breaking a bone?